China experts consensus on the diagnosis and treatment of advanced stage primary lung cancer (2016 version)

Yuankai Shi(Chinese Academy of Medical Sciences & Peking Union Medical College), Yu Huang(Southern Medical University), Yunpeng Liu(First Hospital of China Medical University), Xiaohong Han(Chinese Academy of Medical Sciences & Peking Union Medical College), Wenhua Xiao(First Affiliated Hospital of Chinese PLA General Hospital), Baohui Han(Shanghai Jiao Tong University), Bo Jia(Guangdong Province Stomatological Hospital), Caicun Zhou(Tongji University), Yi Hu(Union Hospital), Gongyan Chen, Milu Wu(Qinghai University Affiliated Hospital), Gang Wu(Hubei University of Chinese Medicine), Zhengtang Chen(Army Medical University), Zongmei Zhou(Chinese Academy of Medical Sciences & Peking Union Medical College), Dong Wang(Army Medical University), Chengping Hu(Central South University), Qisen Guo(Shandong Tumor Hospital), Wěi Li(Shougang (China)), Shan Li(Jiujiang University), Xuan Zeng(Peking Union Medical College Hospital), Kai Li(China Medical University), Zheng Wang(Shanghai Jiao Tong University), Li Zhang(Tianjin Chest Hospital), Wei Liu(Academy of Military Medical Sciences), You Lü(Sichuan University), Rongcheng Luo(Hebei Medical University), Jinming Yu(Shandong First Medical University), Changli Wang(Tianjin Medical University Cancer Institute and Hospital), Jifeng Feng(Zhejiang Cancer Hospital), Yiping Zhang(Henan Normal University), Xiuyi Zhi(Roswell Park Comprehensive Cancer Center), Qiong Zhao(Zhejiang University), Shucai Zhang(Northeastern University), Dongmei Lin(Chinese Academy of Medical Sciences & Peking Union Medical College), Mengzhao Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Ning Wu(Regeneron (United States)), Ziping Wang(University of Science and Technology of China), Xiaomei Li(Shengli Oilfield Central Hospital), Ying Han(Fujian University of Traditional Chinese Medicine), Xia Song(Shanxi Provincial Cancer Hospital), Ping Yu(Sichuan Cancer Hospital), Cheng Huang(Army Medical University), Yan Sun(Chinese Academy of Medical Sciences & Peking Union Medical College), Cuimin Ding(Hebei Medical University), Xiaoqing Liu(Chinese PLA General Hospital), Jianhua Chang(Shanghai Medical College of Fudan University), Cunde Wang(Yangzhou University), Shujun Yang(Henan Cancer Hospital), Enxiao Li(First Affiliated Hospital of Xi'an Jiaotong University)
Asia-Pacific Journal of Clinical Oncology
November 7, 2016
10.1111/ajco.12608
Cited by 44

Related Papers

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2019|3.4k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
HIF-1α pathway: role, regulation and intervention for cancer therapy
|Acta Pharmaceutica Sinica B|2015|1.9k
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
|The Lancet Oncology|2015|1.6k